•  

Posts Tagged: China

Triphase announces Celgene collaborations and license deal with PharmAbcine

Triphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, announced October 27, 2014 new and expanded strategic collaborations with Celgene Corporation. This announcement was covered in Genetic Engineering and Biotechnology News (GEN), BioCentury Extra (no link available), Pharmaceutical Business Review (no link available), Scrip and BioWorld Today (no link available). It builds on Triphase's original collaborative agreement with Celgene in January 2014. The company has also announced a new global license for a fully human, bi-specific ... Read more

XLV Diagnostics Inc. secures $3 million Series A from Boston-based investor

THUNDER BAY, ON (May 28,2014) – XLV Diagnostics Inc., a MaRS Innovation (MI) start-up company based in Thunder Bay and specializing in low-cost, next-generation digital mammography machines, has closed a $3 million Series A investment round with Boston-based Bernard M. Gordon Charitable Remainder Unitrust. The funding will support continued product development and regulatory approval. XLV’s product will provide mammography image quality equivalent to top-of-the-line mammography machines currently in use, and will do so at a fraction of the cost of current generation ... Read more

MI’s Rafi Hofstein featured in Biotechnology Focus

In a January 24, 2014 Biotechnology Focus cover article, author Shawn Lawrence discusses MaRS Innovation President and CEO Dr. Raphael (Rafi) Hofstein's recent visit to learn more of the emerging science and technology markets in Singapore and Japan. The trip allowed Hofstein to discuss current MI projects, specifically start-ups XLV Diagnostics Inc. and DVLR Therapeutics Inc., whose products could benefit from Singapore's proximity to medical technology markets in India and China. Hofstein joined other delegates from Canada, including Dr. Mark Poznansky, president and CEO of the ... Read more

Is screening air travellers effective in containing a pandemic?

Toronto Star covers Khan's new WHO paper on H1N1 outbreak Dr. Kamran Khan, founder of BioDiaspora and an infectious disease physician and scientist at St. Michael’s Hospital, is among the experts studying the emergence of the H7N9 bird flu outbreak in China and the new coronavirus in the Middle East and Europe. Global News National also covered this story on April 11, 2013. Watch Beatrice Politi and Carmen Chai's report, "Canadian scientists pioneer new formula in airport disease screening," on the Global website. The ... Read more

BioDiaspora Founder: Travellers unlikely to bring H7N9 bird flu to Canada

Dr. Kamran Khan, founder of BioDiaspora and an infectious disease physician and scientist at St. Michael's Hospital, is among the experts studying the emergence of the H7N9 bird flu outbreak in China. Jennifer Yang interviewed Khan in today's Toronto Star about the likelihood of the disease being easily transmitted from human to human or arriving in Canada, as SARS did in 2003. Here's an excerpt: “This isn’t necessarily an event that poses a significant risk to Canada, at least based on all the current ... Read more

Video: Dr. Raphael Hofstein’s interview with IBTimesTV

Technology reporter Alastair Charlton speaks to Dr. Raphael Hofstein, president and CEO of MaRS Innovation, about how Tech City in the U.K. can learn from Canada's hub for science, technology and social entrepreneurs. (more…) Read more

ClevrU partners with Schulich School of Business professors to target online education market

MaRS Innovation and York University’s commercialization office support new partnership In the age of ITunes, videotaping lectures or converting existing textbooks into e-books won’t make you the market leader in online education. Thanks to a new partnership between ClevrU, and NewMindsets Inc., facilitated by MaRS Innovation and York University’s commercialization office, Canadian technology and content promises to establish the second-generation online learning standard for millions of students worldwide. (more…) Read more

Business Without Borders highlights ScarX Therapeutics’ Chinese co-development partnership

ScarX Therapeutics, a spin-off company created by MaRS Innovation and The Hospital for Sick Children (SickKids), was profiled by Business Without Borders on September 25, 2012. Sean Fine's article examines the strategic funding partnership MI pursued with NovoTek Therapeutics Inc. (NovoTek) in China to develop the anti-scarring cream, which was discovered by researchers at SickKids. A multibillion-dollar market may await ScarX, a Toronto biomedical start-up, but first it had to figure out how to finance the development of its unique cream that reduces scarring ... Read more

MaRS Innovation Forms Strategic Drug-Development Partnership with NovoTek Therapeutics Inc. in China

MaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek)  have announced a strategic partnership to co‐develop, and bring to the Chinese market, a novel therapeutic cream aimed at reducing scar formation post surgery. This project was covered in The Globe and Mail on May 7, 2012. (more…) Read more